ProShare Advisors LLC Has $623,000 Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)

ProShare Advisors LLC raised its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 22,398 shares of the company's stock after buying an additional 5,477 shares during the quarter. ProShare Advisors LLC's holdings in Akero Therapeutics were worth $623,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. boosted its position in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after purchasing an additional 450 shares in the last quarter. Hsbc Holdings PLC increased its position in Akero Therapeutics by 8.5% during the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock worth $220,000 after buying an additional 621 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Akero Therapeutics by 1.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company's stock worth $1,153,000 after purchasing an additional 637 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock valued at $584,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Akero Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 95,600 shares of the company's stock valued at $2,660,000 after acquiring an additional 1,100 shares during the last quarter.

Insider Buying and Selling at Akero Therapeutics

In related news, VP Patrick Lamy sold 4,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $50.00, for a total value of $200,000.00. Following the completion of the transaction, the vice president now directly owns 33,492 shares of the company's stock, valued at $1,674,600. This represents a 10.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Catriona Yale sold 10,000 shares of Akero Therapeutics stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $39.30, for a total value of $393,000.00. Following the sale, the insider now directly owns 95,034 shares in the company, valued at $3,734,836.20. The trade was a 9.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 223,208 shares of company stock valued at $9,313,294 in the last ninety days. Company insiders own 7.94% of the company's stock.

Analyst Ratings Changes

AKRO has been the topic of several research reports. UBS Group increased their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Citigroup dropped their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America boosted their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, HC Wainwright raised their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has a consensus rating of "Buy" and a consensus target price of $82.50.

Akero Therapeutics Stock Performance

NASDAQ:AKRO traded up $1.15 during midday trading on Friday, reaching $49.18. 221,471 shares of the company traded hands, compared to its average volume of 968,327. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of -13.07 and a beta of -0.12. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The company has a fifty day moving average price of $41.09 and a 200 day moving average price of $38.60.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $1.91. On average, analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.